Unanswered questions regarding the management of sunitinib-induced hypothyroidism

被引：0
|
作者：
David Garfield
Aleck Hercbergs
Paul Davis
机构：
[1] D Garfield is a medical oncologist affiliated with the University of Colorado Health Sciences Center,
[2] A Hercbergs is a Radiation Oncologist at the Cleveland Clinic Foundation,undefined
[3] Cleveland,undefined
[4] OH,undefined
[5] P Davis is Senior Associate Dean for Clinical Research and Professor of Medicine at Albany Medical College,undefined
[6] Albany,undefined
[7] NY,undefined
[8] USA.,undefined
来源：
Nature Clinical Practice Oncology | 2007年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Hypothyroidism seems to be a risk of sunitinib therapy for cancer. The authors of this Viewpoint review the evidence for the occurrence of hypothyroidism in this setting and discuss possible actions of thyroid hormone replacement in the cancer patient.
引用
收藏
页码：674 / 674
相关论文
共 50 条
  • [41] Sunitinib-induced Thyrotoxicosis - A not so Rare Entity
    Jazvic, Marijana
    Prpic, Marin
    Jukic, Tomislav
    Murgic, Jure
    Jaksic, Blanka
    Kust, Davor
    Prgomet, Angela
    Bolanca, Ante
    Kusic, Zvonko
    ANTICANCER RESEARCH, 2015, 35 (01) : 481 - 485
  • [42] Sunitinib-induced Acute Psychosis: Case Report
    Kunene, Victoria
    Porfiri, Emilio
    CLINICAL GENITOURINARY CANCER, 2011, 9 (01) : 70 - 72
  • [43] Sunitinib-induced severe hypoglycemia in a diabetic patient
    Demirci, Ayse
    Bal, Oznur
    Durnali, Ayse
    Ekinci, Ahmet S.
    Esbah, Onur
    Alkis, Necati
    Oksuzoglu, Berna
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2014, 20 (06) : 469 - 472
  • [44] Sunitinib-Induced Microangiopathic Hemolytic Anemia with Fatal Outcome
    Talebi, Tony N.
    Stefanovic, Alexandra
    Merchan, Jaime
    Lian, Eric
    Silva, Orlando
    AMERICAN JOURNAL OF THERAPEUTICS, 2012, 19 (04) : E143 - E145
  • [45] Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction
    Daiei Takahashi
    Kiyotaka Nagahama
    Yukio Tsuura
    Hiroyuki Tanaka
    Teiichi Tamura
    Clinical and Experimental Nephrology, 2012, 16 : 310 - 315
  • [46] Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma
    Arnaud, Laurent
    Schartz, Noel E. C.
    Kerob, Delphine
    Lebbe, Celeste
    Bousquet, Guilhem
    Sarandi, Farid
    Verola, Olivier
    Madelaine, Isabelle
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) : 1569 - 1571
  • [47] Sunitinib-Induced Microangiopathic Hemolytic Anemia: A Case Report
    Korkmaz, Serdal
    Kilickap, Saadettin
    Terzi, Hatice
    Sencan, Mehmet
    ERCIYES MEDICAL JOURNAL, 2014, 36 (02) : 88 - 90
  • [48] Sunitinib-induced pyoderma gangrenosum-like ulcerations
    Akanay-Diesel, S.
    Hoff, N.
    Kuerle, S.
    Haes, J.
    Erhardt, A.
    Haeussinger, D.
    Schulte, K.
    Homey, B.
    ALLERGY, 2011, 66 : 318 - 318
  • [49] Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity
    van Erp, Nielka P.
    Eechoute, Karel
    van der Veldt, Astrid A.
    Haanen, John B.
    Reyners, An K. L.
    Mathijssen, Ron H. J.
    Boven, Epie
    van der Straaten, Tahar
    Baak-Pablo, Renee F.
    Wessels, Judith A. M.
    Guchelaar, Henk-Jan
    Gelderblom, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) : 4406 - 4412
  • [50] Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity
    van Erp, N.
    Mathijssen, R. H.
    van der Veldt, A. A.
    Haanen, J. B.
    Reyners, A. K.
    Eechoute, K.
    Boven, E.
    Wessels, J. A.
    Guchelaar, H.
    Gelderblom, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345